Abstract Infectious diseases are becoming a major menace to the state of health 4 worldwide, with difficulties in effective treatment especially of nosocomial infec-5 tions caused by Gram negative bacteria being increasingly reported. Inadequate 6 permeation of anti-infectives into or across the Gram negative bacterial cell enve-7 lope, due to its intrinsic barrier function as well as barrier enhancement mediated 8 by resistance mechanisms, can be identified as one of the major reasons for insuf-9 ficient therapeutic effects. Several in vitro, in silico and in cellulo models are cur-10 rently employed to increase knowledge of anti-infective transport processes into or 11 across the bacterial cell envelope, however all such models exhibit drawbacks or 12 have limitations with respect to the information they are able to provide. Thus, 13 new approaches which allow for more comprehensive characterization of anti-14 infective permeation processes (and as such, would be usable as screening meth-15 ods in early drug discovery and development) are desperately needed. Further-16 more, delivery methods or technologies capable of enhancing anti-infective per-17 meation into or across the bacterial cell envelope are required. In this respect, 18 particle-based carrier systems have already been shown to provide the opportunity 19 to overcome compound related difficulties and allow for targeted delivery. In ad-20 dition, formulations combining efflux pump inhibitors or antimicrobial peptides 21 with anti-infectives show promise in the restoration of antibiotic activity in re-22 sistant bacterial strains. Despite considerable progress in this field however, the 23 design of carriers to specifically enhance transport across the bacterial envelope or 24 to target difficult to treat (e.g. intracellular) infections remains an urgently needed 25 area of improvement. What follows is a summary and evaluation of the state of the 26 art of both bacterial permeation models and advanced anti-infective formulation 27 strategies, together with an outlook for future directions in these fields. 28
Introduction

76
The effective treatment of infectious diseases by means of anti-infective drug 77 therapies is currently associated with a significant and increasing level of difficul-78 ty. The incidence of nosocomial infections caused in particular by pathogenic bac-79 teria is an indicator of this problem. In Germany alone 400 000 -600 000 hospi-80 tal-acquired, bacterial infections occur per year; 7500 -15 000 of such cases are 81 in fact lethal (Akademie der Wissenschaften and Deutsche Akademie der 82 Naturforscher 2013). These statistics are mainly due to the increasing incidence of 83 bacterial resistance to drug therapy, leading to a lack of sufficiently active anti-84 infective treatment options. Gram negative bacteria are particularly problematic in 85 this respect: as an example, carbapenem-resistant-Enterobacteriaceae (CRE, for 86 abbreviations see Table 1 ) are capable of evading the action of almost all current-87 ly-available antibiotics. This dire trend leads to the occurrence of nearly un-88 treatable infections, with only two 'last resort' antibiotics available (tigecycline 89 and colistin) -neither of which are effective in every patient (McKenna 2013) . We 90 are therefore faced with a major global challenge with respect to the successful 91 treatment of Gram negative bacterial infections (Wellington et al. 2013 ). 92 93
While resistance to anti-infective drug therapies is without doubt the primary 94 threat to effective infectious disease treatment, the evolution of resistance is com-95 pounded by a number of additional factors. Firstly, the successful delivery of anti-96 infectives to their site of action constitutes a challenging and complicated task, 97 even in the case of a wild type bacterium. This is due to the fact that the bacterial 98 cell envelope, especially that of Gram negative bacteria, works intrinsically as a 99 complex and significant biological barrier to the effective delivery of anti-100 infective compounds and formulations (see section 2.1, Nelson et al. 2009 ). The 101 occurrence of several resistance mechanisms such as up-regulation of efflux pump 102 expression, down-regulation or alteration of the expression of transport and chan-103 nel-forming proteins (e.g. porins) and the production of enzymes (e.g. ß-104 lactamase) within this envelope structure therefore acts to compound an already 105 existing problem for anti-infectives which must penetrate into or entirely through 106 the bacterial envelope in order to reach their site of action (Dever and Dermody 107 1991). As a further factor for consideration, from the so-called golden age of anti-108 biotic discovery -lasting from the 1950s to the 1960s (Fischbach and Walsh 2009) 
109
-until the introduction of the oxazolidinones in 2000, no new anti-infective class 110 was able to successfully reach the market. This low flow within the antibiotic de-111 velopment pipeline continues today, meaning that the diminishing pool of effec-112 tive therapies is not being replenished by newly-emerging treatment options. 113
The above described factors contributing towards the problematic nature of effec-114 tive infection treatment can collectively be regarded as symptoms of a bacterial 115 bioavailability problem. Such a bioavailability issue draws attention to two signif-116 icant necessities in the area of anti-infective research. 117
The first is the desperate need for new models and strategies to better investigate 118 and characterize the trafficking of anti-infectives into or across the bacterial cell 119 envelope, in order to increase collective knowledge of the envelope as a barrier 120 which needs to be overcome. As a second need, novel anti-infective candidates 121
with new modes of action are required, as are new delivery strategies which ena-122 ble effective penetration into or across the Gram negative bacterial cell envelope. 123
The current document will attempt to address aspects of both research needs, out-124 lining the state of the art in each area as well as potential or actual future research 125 directions. Specific emphasis will continue to be given to Gram negative bacteria 126 as particularly problematic pathogens. 127 128 
Bacterial Cell Envelope
241
As detailed above, the Gram negative bacterial cell envelope works as an effective 242 biological barrier to the successful delivery of anti-infectives to their target site. 243
The fundamental existing barrier properties of the envelope are also able to be fur-244 ther increased through the up-regulation of resistance mechanisms. Therefore, in 245 addition to well-established and commonly used efficacy testing approaches, it is 246 of considerable interest to obtain a greater and more detailed level of knowledge 247 regarding rate, extent and mechanisms of the processes by which anti-infectives 248 permeate (actively or passively) across the envelope. Models which mimic the cell 249 envelope and so enable provision of such information can thus help to facilitate 250 the rational design of anti-infective agents, capable of overcoming intrinsic deliv-251 ery difficulties/bacterial resistance mechanisms. Such models could additionally 252 contribute useful information to early anti-infective drug discovery processes. The 253 currently existing and employed models of the envelope structure, used in order to 254 provide permeation and transport information, will be described in the following 255 section. The needs which are unmet by these existing models will also be men-256 tioned. 257
Electrophysiology Studies 258 259
Electrophysiological studies are applied to obtain information about the transport 260 of anti-infectives through single porins. The principle of electrophysiology is 261 based on the reconstitution of such channel forming proteins -mostly OmpF, as 262 the main porin responsible for the passive OM permeation of many anti-infectives 263 such as the ß-lactams and quinolones -into planar lipid bilayers ( Figure 2A ). Such 264 bilayers mostly consist of phosphatidylcholine (PC), and are made for example by 265 bursting porin-containing proteoliposomes across an aperture within a solid sup-266 port (Kreir et al. 2008 ). An external voltage is then applied across the aperture-267 spanning membrane, which causes an ion flux through the inserted porin channel. 268
The strength of the resulting current allows for the provision of information re-269 garding the channel structure and its functional properties in a variety of experi-270 mental settings (e.g. ranges of salt concentration, pH). The technique is additional-271 ly able to be automated (Mach et al. 2008a ) and can be further optimized for 272 example by applying the porin-containing supported lipid bilayer system into glass 273 nanopipets (Gornall et al. 2011 ). In addition to providing information on porin 274 structure and function, anti-infective passage kinetics through the bilayer-275 reconstituted porins can be studied by the use of high resolution ion-current fluc-276 tuation analysis (Pages et al. 2008 ). In general, the permeation of anti-infective 277 compounds through porins is detected by a decrease in current due to an occlusion 278 of the porin channel by the permeating compound. Electrophysiological studies 279 therefore facilitate determination of the direct translocation of charged molecules 280 through porin channels. They additionally allow for evaluation of the interaction 281 of anti-infectives with the constriction zone of porins (the narrowest part of the 282 porin channel, which mediates the size-wise exclusion of molecule permeation 283 across the OM) in particular. The relative affinity of different anti-infective com-284 pounds for specific porins can also be elucidated using electrophysiological stud-285
ies 
In Silico Methods 427 428
Besides the so-far described in vitro models, in silico approaches are also utilized 429 to investigate the impact and interaction of various lipid species within simulated 430 bilayers (which in turn may have a bearing on anti-infective permeability). They 431 are furthermore applied to inform the development of membrane models which 432 more closely and accurately reflect the structure and components of the IM and 433
OM. In silico approaches may also be employed to determine the affinity and/or 434 translocation of anti-infectives with or across porin channels, as alluded to previ-435 ously (see 3.1.1). The OM has also been simulated in various in silico studies, starting with models 457 consisting of LPS alone and followed by simulations using a combination of a PL 458 inner leaflet and LPS outer leaflet to more accurately reflect the asymmetric OM 459 structure. These models have largely been used to study properties such as interac-460 tions between LPS molecules in the OM, the stabilization effect of divalent cati-461 ons on the membrane structure (and resulting barrier properties), the effect of elec-462 troporation on the barrier function of protein-free, asymmetric membrane 463 structures and the impact of OM enzymes as well as proteins on membrane integ-464 rity ( ever that such an approach is still limited to an 'inside/outside' distinction of anti-510 infective location, and determination of anti-infective permeation with any higher 511 degree of spatial resolution remains extremely difficult. 512
Shortcomings of Existing Models and Future Directions 513 514
The current modeling approaches discussed in this section help to get a better un-515 derstanding of permeation processes across various sub-structures of the Gram 516 negative bacterial cell envelope. However, drawbacks and unmet needs can be 517 mentioned for each of the above categories of models available to date. As a gen-518 eral comment, the in vitro and in silico modeling approaches described here most-519 ly focus on producing or simulating structures which approximate either the IM or 520 OM, and not the cell envelope as a whole -or, in the small number of cases where 521 the overall envelope structure is approximated, the resulting model is often tai-522 lored to the examination of intra-membrane interactions or causes of membrane 523 disruption. In addition, many such models consist of a phospholipid composition 524 which deviates from that found in cellulo, and, while it has been mentioned that 525 attempts are made in some cases to represent the asymmetric structure of the OM 526 in models of this membrane component, many models still neglect to feature this 527 important aspect. Furthermore, due to considerable difficulties associated with 528 scale and resolution, the vast majority of models to date allow for a qualitative 529 prediction of anti-infective permeation and transport, rather than for quantification 530 of such processes. In cellulo approaches where multiple planktonic cells rather 531 than single cells are used have proven very useful in order to provide detailed and 532 in some cases, quantitative insights into permeation processes; however, as men-533 tioned, such methods generally rely on an average permeation within a bacterial 534 population to draw conclusions regarding single cell permeation. Furthermore, 535 current in cellulo approaches do not allow for evaluation of the specific extent of 536 anti-infective permeation into the envelope structure. Hence, models which mimic 537 the overall envelope in terms of their PL composition and structure, which are de-538 signed to explicitly investigate and quantify transport and permeation processes, 539
and which are able to discriminate between active and passive permeation of anti-540 infective compounds and delivery systems in both a spatially-and kinetically-re-541 solved manner are desperately needed. 542 543
Improving Bacterial Bioavailability using Advanced Delivery
544
Strategies
545
In addition to employment and development of bacterial permeation models, a di-546 rect research focus is also placed on anti-infective therapies themselves in an at-547 tempt to overcome the cell envelope structure, achieve an increase in intra-548 bacterial drug concentrations, and, in doing so, improve bioavailability in bacteria. 549
In this respect, the search for new anti-infective drug candidates as well as the in-550 vestigation of alternative approaches to antibiotic therapy continues, as presented 551 and discussed in detail elsewhere. Additional strategies, such as the re-formulation 552 of currently available anti-infectives with permeation-enhancing excipients or the 553 application of advanced carrier systems, also represent promising research direc-554 tions. Such strategies are particularly valuable in instances where bacterial bioa-555 vailability issues cannot be directly resolved by the introduction of new molecules, 556 or through modification of existing anti-infective structures using medicinal chem-557 istry approaches. As such, a number of currently investigated advanced formula-558 tion strategies are presented below. 559
Efflux Pump Inhibitors 560 561
As mentioned in section 2.1, efflux in wild-type as well as drug resistant Gram 562 negative bacteria is mainly mediated by the RND superfamily of efflux transport-563 ers. The use of formulations incorporating efflux pump inhibitors (EPIs) which are 564 able to interact with such pumps, decreasing anti-infective efflux and subsequently 565 leading to higher intracellular drug levels, therefore represents a useful strategy to 566 restore anti-infective potency. The inhibition of pumps as mediated by EPIs can be 567 described as occurring by two major modes of action. One can be classified as 568 biological, in which EPIs act to decrease the expression of the pumps themselves 569 by inhibiting transcription or translation via antisense oligonucleotides. A pharma-570 cological mechanism represents the second mode of action, in which EPIs operate 571 through direct interaction with the pump affinity site, acting for example to col-572 lapse the efflux energy or to competitively or non-competitively inhibit the efflux 573 process (Van Bambeke et al. 2010). EPIs can be further differentiated into inhibi-574 tors with a narrow spectrum of activity, being used as diagnostic tools to detect ac-575 tive efflux, or inhibitors with a broad spectrum of action, which could be poten-576 tially useful in clinical settings. The further ability of EPIs to restore the activity of 577 simultaneously applied anti-infectives (being visible for example in a decrease of 578 minimum inhibitory concentration (MIC)) makes them an even more promising 579 approach as a means to increase anti-infective bacterial bioavailability. Examples 580 of known EPIs include analogues or lead structures of tetracyclines or fluoroquin-581 olones, arylpiperidine and phenothiazine derivatives as well as peptidomimetics 582 (Pages and Amaral 2009) . Peptidomimetics with phenylalanine arginyl ß-583 naphthylamine (PAßN) as lead compound represent the first efflux inhibiting 584 group which showed an effective blocking of fluoroquinolone efflux in a RND 585 over-expressing strain of Pseudomonas aeruginosa (Renau et al. 2002) . Currently, 586
EPIs are used primarily as in vitro screening tools; their potential use in the clinic 587 is still under investigation due to the existence of several challenging factors. The 588 primary obstacle to the use of EPIs in a clinical setting is that of toxicity -most of 589 the known EPIs to date need to be used in high concentrations, which may lead to 590 possible toxic effects. Their use in combination with anti-infectives also demands 591 the absence of interactions between the EPI and the anti-infective compound, as 592 well as comparability in their pharmacokinetic profiles. 593
Antimicrobial Peptides 594 595
The use of the previously mentioned AMPs, either alone or especially in synergis-596 tic combinations with conventional anti-infectives, represents a further strategy to 597 overcome anti-infective bioavailability problems by enhancing their transport 598 across the bacterial cell envelope. AMPs can be further used as stimuli for the in-599 nate immune system, or as endotoxin-neutralizing agents (Gordon et al. 2005 ). 600
AMPs in themselves are generally small cationic peptides which can be derived 601 from humans, bacteria, or even viruses (Yount and Yeaman 2004) . Their mode of 602 action as bioavailability-potentiating agents is primarily based on the initiation of 603 bacterial membrane perturbation, an effect mainly mediated by electrostatic inter-604 actions between the positively charged peptide and the negatively charged LPS of 605 the OM. Such interactions lead to a destabilization of the OM by displacing pre-606 sent divalent cations, which facilitates penetration of AMPs and any other associ-607 ated compounds through the OM structure. Following this self-promoted uptake 608 through the OM, the further association of AMPs with the outer leaflet of the IM 609 followed by the formation of micelle-like aggregates finally leads to a rupture of 610 the bacterial envelope. This allows either for bacterial killing, or for an even fur-611 ther enhanced uptake of the simultaneously administered anti-infective. A non-612 destructive action of AMPs, facilitated by binding to DNA or RNA, is also further 613 described (Hancock 1997; Hancock and Chapple 1999 The combination of EPIs and AMPs with conventional or even new anti-infectives 696 may result in a reduction of undesirable intrinsic anti-infective properties as well 697
as an increased bacterial permeation, leading to higher intracellular drug levels 698 and so an enhanced bacterial bioavailability. Furthermore, carrier systems are able 699 to provide a means of circumventing compound related difficulties, such as unfa-700 vorable pharmacokinetics, and to achieve high intracellular drug levels. In this 701 manner such advanced formulation strategies may act to increase the bioavailabil-702 ity of anti-infectives, and for this reason continue to be employed and developed. 703
The treatment of intracellular infections as well as the specific development of 704 permeability enhancing carriers constitutes an important direction of future appli-705 cations. 706
Conclusion and Outlook
707
This paper has aimed to give an overview of current difficulties in the treatment of 708 infectious diseases, in particular those caused by Gram negative bacteria. In this 709 respect, the significant bioavailability problems of anti-infective compounds -de-710 fined as an inadequate delivery to their (mainly intra-bacterial) sites of action -711 largely stem from the complex nature of the cell envelope and its formidable bar-712 rier function. This barrier function may be even further enhanced by the evolution 713 of resistance mechanisms. Numerous models -in vitro, in silico as well as in cellu-714 lo in nature -may be used in order to increase understanding of permeation pro-715 cesses into or across the envelope, as well as to enable evaluation of how the cell 716 envelope in its entirety or as its individual sub-structures acts as a permeation lim-717 iting factor. However, a paucity of quantitative approaches which accurately mim-718 ic the overall envelope structure has to be mentioned, meaning that obtained in-719 formation may lack comprehensiveness. Therefore, new permeation models which 720 more accurately represent the various structural components of the Gram negative 721 bacterial cell envelope, and which are further able to provide quantitative, kinet-722 ically-and spatially-resolved permeation data are desperately needed. Such mod-723 els would also ideally allow for discrimination between active and passive 724 transport processes, and would be applicable as high throughput screening meth-725 ods in early drug discovery. With respect to anti-infective compounds themselves, 726 the combination of EPIs or AMPs with conventional anti-infectives presents a 727 promising strategy in overcoming bacterial bioavailability problems, enabling the 728 restoration of anti-infective activity even in resistant strains. Particulate delivery 729 systems may similarly facilitate an increase in anti-infective bioavailability, by 730 acting to overcome drawbacks related to the free drug itself; such carrier systems 731 may additionally facilitate a targeted delivery of anti-infectives. Anti-infective 732 formulations which are designed to particularly increase the permeation or 733
